A pivotal phase 3 study of cabozantinib to treat patients with advanced differentiated thyroid carcinoma (DTC).

Trial Profile

A pivotal phase 3 study of cabozantinib to treat patients with advanced differentiated thyroid carcinoma (DTC).

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 27 Feb 2018 New trial record
    • 26 Feb 2018 Accoding to a Exelixis media release, company plans to initiate the trial later in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top